Jubilant Life sees cancer drug trials by end-2013

REUTERS - Jubilant Life Sciences said late on Wednesday its new drug aimed at treating prostate cancer is expected to enter clinical trials by the end of this year in the United States.

U.S.-based Endo Pharmaceuticals and Jubilant's Bangalore unit are jointly developing the drug. The U.S. Food and Drug Administration has accepted the filing for this investigational new drug application, Jubilant said in a statement.

(Reporting by Kaustubh Kulkarni in Mumbai; Editing by Subhranshu Sahu)